http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011013668-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41100b9f750ae246f452a73ca61a4970
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_156a9a040d2255ebe52e644906b5becf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b840490ce4e7830aa852a942094b9df0
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-275
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-275
filingDate 2010-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3936806f9832f9728dff43d91af99246
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ded8746f77f6ed09cabcb7d07afb8b2a
publicationDate 2011-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2011013668-A1
titleOfInvention Pharmaceutical composition for treatment of ischemic events
abstract Disclosed is a therapeutic pharmaceutical composition comprising a thrombolytic agent and an inhibitor capable of inhibiting a signaling that is mediated by a receptor of a vascular endothelial growth factor (VEGF). The therapeutic pharmaceutical composition can be used for the treatment of severe ischemic events including cerebral infarction, cardiac infarction and pulmonary embolism.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10617756-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9913899-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077188-B2
priorityDate 2009-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007128526-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H11515010-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396401
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20055127
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13013858
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226434160

Total number of triples: 36.